Use my Search Websuite to scan PubMed, PMCentral, Journal Hosts and Journal Archives, FullText.
Kick-your-searchterm to multiple Engines kick-your-query now !>
A dictionary by aggregated review articles of nephrology, medicine and the life sciences
Your one-stop-run pathway from word to the immediate pdf of peer-reviewed on-topic knowledge.

suck abstract from ncbi


10.1128/CMR.00162-20

http://scihub22266oqcxt.onion/10.1128/CMR.00162-20
suck pdf from google scholar
33055231!7566896!33055231
unlimited free pdf from europmc33055231    free
PDF from PMC    free
html from PMC    free

suck abstract from ncbi

pmid33055231      Clin+Microbiol+Rev 2020 ; 34 (1): ä
Nephropedia Template TP

gab.com Text

Twit Text FOAVip

Twit Text #

English Wikipedia


  • Remdesivir against COVID-19 and Other Viral Diseases #MMPMID33055231
  • Malin JJ; Suarez I; Priesner V; Fatkenheuer G; Rybniker J
  • Clin Microbiol Rev 2020[Dec]; 34 (1): ä PMID33055231show ga
  • Patients and physicians worldwide are facing tremendous health care hazards that are caused by the ongoing severe acute respiratory distress syndrome coronavirus 2 (SARS-CoV-2) pandemic. Remdesivir (GS-5734) is the first approved treatment for severe coronavirus disease 2019 (COVID-19). It is a novel nucleoside analog with a broad antiviral activity spectrum among RNA viruses, including ebolavirus (EBOV) and the respiratory pathogens Middle East respiratory syndrome coronavirus (MERS-CoV), SARS-CoV, and SARS-CoV-2. First described in 2016, the drug was derived from an antiviral library of small molecules intended to target emerging pathogenic RNA viruses. In vivo, remdesivir showed therapeutic and prophylactic effects in animal models of EBOV, MERS-CoV, SARS-CoV, and SARS-CoV-2 infection. However, the substance failed in a clinical trial on ebolavirus disease (EVD), where it was inferior to investigational monoclonal antibodies in an interim analysis. As there was no placebo control in this study, no conclusions on its efficacy in EVD can be made. In contrast, data from a placebo-controlled trial show beneficial effects for patients with COVID-19. Remdesivir reduces the time to recovery of hospitalized patients who require supplemental oxygen and may have a positive impact on mortality outcomes while having a favorable safety profile. Although this is an important milestone in the fight against COVID-19, approval of this drug will not be sufficient to solve the public health issues caused by the ongoing pandemic. Further scientific efforts are needed to evaluate the full potential of nucleoside analogs as treatment or prophylaxis of viral respiratory infections and to develop effective antivirals that are orally bioavailable.
  • |Adenosine Monophosphate/*analogs & derivatives/pharmacokinetics/pharmacology[MESH]
  • |Alanine/*analogs & derivatives/pharmacokinetics/pharmacology[MESH]
  • |Antiviral Agents/pharmacokinetics/*pharmacology[MESH]
  • |Betacoronavirus/drug effects/growth & development/pathogenicity[MESH]
  • |COVID-19[MESH]
  • |Clinical Trials as Topic[MESH]
  • |Compassionate Use Trials/methods[MESH]
  • |Coronavirus Infections/*drug therapy/mortality/pathology/virology[MESH]
  • |Drug Administration Schedule[MESH]
  • |Ebolavirus/drug effects/growth & development/pathogenicity[MESH]
  • |Hemorrhagic Fever, Ebola/*drug therapy/mortality/pathology/virology[MESH]
  • |Humans[MESH]
  • |Middle East Respiratory Syndrome Coronavirus/drug effects/growth & development/pathogenicity[MESH]
  • |Pandemics[MESH]
  • |Patient Safety[MESH]
  • |Pneumonia, Viral/*drug therapy/mortality/pathology/virology[MESH]
  • |SARS-CoV-2[MESH]
  • |Severe Acute Respiratory Syndrome/*drug therapy/mortality/pathology/virology[MESH]
  • |Severe acute respiratory syndrome-related coronavirus/drug effects/growth & development/pathogenicity[MESH]
  • |Survival Analysis[MESH]


  • DeepDyve
  • Pubget Overpricing
  • suck abstract from ncbi

    Linkout box